570 related articles for article (PubMed ID: 33639976)
21. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development.
Zhang Z; Zhou L; Liu Q; Zheng Y; Tan X; Huang Z; Guo M; Wang X; Chen X; Liang S; Li W; Song K; Yan K; Li J; Li Q; Zhang Y; Yang S; Cai Z; Dai M; Xian Q; Shi ZL; Xu K; Lan K; Chen Y
Emerg Microbes Infect; 2024 Dec; 13(1):2353302. PubMed ID: 38753462
[TBL] [Abstract][Full Text] [Related]
22. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J
J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775
[TBL] [Abstract][Full Text] [Related]
23. Generation of a lethal mouse model expressing human ACE2 and TMPRSS2 for SARS-CoV-2 infection and pathogenesis.
Jeong GU; Hwang I; Lee W; Choi JH; Yoon GY; Kim HS; Yang JS; Kim KC; Lee JY; Kim SJ; Kwon YC; Kim KD
Exp Mol Med; 2024 May; 56(5):1221-1229. PubMed ID: 38816566
[TBL] [Abstract][Full Text] [Related]
24. Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: A versatile and practical infection model for antiviral research and beyond.
Salgado-Benvindo C; Tas A; Zevenhoven-Dobbe JC; van der Meer Y; Sidorov IA; Leijs AA; Wanningen P; Gelderloos AT; van Kasteren PB; Snijder EJ; van Hemert MJ
Antiviral Res; 2024 Jul; 227():105903. PubMed ID: 38723907
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
26. Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions.
Bhatt AN; Kumar A; Rai Y; Kumari N; Vedagiri D; Harshan KH; Chinnadurai V; Chandna S
Life Sci; 2022 Apr; 295():120411. PubMed ID: 35181310
[TBL] [Abstract][Full Text] [Related]
27. Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity.
Diomede L; Baroni S; De Luigi A; Piotti A; Lucchetti J; Fracasso C; Russo L; Bonaldo V; Panini N; Filippini F; Fiordaliso F; Corbelli A; Beeg M; Pizzato M; Caccuri F; Gobbi M; Biasini E; Caruso A; Salmona M
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578326
[TBL] [Abstract][Full Text] [Related]
28. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
Salas Rojas M; Silva Garcia R; Bini E; Pérez de la Cruz V; León Contreras JC; Hernández Pando R; Bastida Gonzalez F; Davila-Gonzalez E; Orozco Morales M; Gamboa Domínguez A; Sotelo J; Pineda B
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477376
[TBL] [Abstract][Full Text] [Related]
29. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.
Chen F; Shi Q; Pei F; Vogt A; Porritt RA; Garcia G; Gomez AC; Cheng MH; Schurdak ME; Liu B; Chan SY; Arumugaswami V; Stern AM; Taylor DL; Arditi M; Bahar I
Mol Syst Biol; 2021 Aug; 17(8):e10239. PubMed ID: 34339582
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
31. Modeling SARS-CoV-2 Infection in Mice Using Lentiviral hACE2 Vectors Infers Two Modes of Immune Responses to SARS-CoV-2 Infection.
Katzman C; Israely T; Melamed S; Politi B; Sittner A; Yahalom-Ronen Y; Weiss S; Abu Rass R; Zamostiano R; Bacharach E; Ehrlich M; Paran N; Nissim L
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062215
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a pangolin SARS-CoV-2-related virus isolate that uses the human ACE2 receptor.
Xia LY; Wang XF; Cui XM; Zhang YM; Wang ZF; Li ET; Fan CF; Song K; Li YG; Ye RZ; Li FX; Zhu DY; Zhang J; Shi ZZ; Zhang MZ; Li LJ; Shen SJ; Jin S; Zhang YW; Fu WG; Zhao L; Wang WH; Wang TC; Wang YC; Jiang JF; Hu YL; Jia N; Gao YW; Cao WC
Sci China Life Sci; 2024 Jul; 67(7):1502-1513. PubMed ID: 38478297
[TBL] [Abstract][Full Text] [Related]
33. mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2.
Hassert M; Geerling E; Stone ET; Steffen TL; Feldman MS; Dickson AL; Class J; Richner JM; Brien JD; Pinto AK
PLoS Pathog; 2020 Dec; 16(12):e1009163. PubMed ID: 33326500
[TBL] [Abstract][Full Text] [Related]
34. Broad-Spectrum Antiviral Activity of 3D8, a Nucleic Acid-Hydrolyzing Single-Chain Variable Fragment (scFv), Targeting SARS-CoV-2 and Multiple Coronaviruses In Vitro.
Lee G; Budhathoki S; Lee GY; Oh KJ; Ham YK; Kim YJ; Lim YR; Hoang PT; Lee Y; Lim SW; Kim JM; Cho S; Kim TH; Song JW; Lee S; Kim WK
Viruses; 2021 Apr; 13(4):. PubMed ID: 33918914
[TBL] [Abstract][Full Text] [Related]
35. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
36. Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice.
Huang K; Zhang Y; Hui X; Zhao Y; Gong W; Wang T; Zhang S; Yang Y; Deng F; Zhang Q; Chen X; Yang Y; Sun X; Chen H; Tao YJ; Zou Z; Jin M
EBioMedicine; 2021 May; 67():103381. PubMed ID: 33993052
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers.
Rosenke K; Leventhal S; Moulton HM; Hatlevig S; Hawman D; Feldmann H; Stein DA
J Antimicrob Chemother; 2021 Jan; 76(2):413-417. PubMed ID: 33164048
[TBL] [Abstract][Full Text] [Related]
38. Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice.
Silvas JA; Vasquez DM; Park JG; Chiem K; Allué-Guardia A; Garcia-Vilanova A; Platt RN; Miorin L; Kehrer T; Cupic A; Gonzalez-Reiche AS; Bakel HV; García-Sastre A; Anderson T; Torrelles JB; Ye C; Martinez-Sobrido L
J Virol; 2021 Aug; 95(17):e0040221. PubMed ID: 34133899
[TBL] [Abstract][Full Text] [Related]
39. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of betanodavirus infection by inhibitors of endosomal acidification.
Adachi K; Ichinose T; Takizawa N; Watanabe K; Kitazato K; Kobayashi N
Arch Virol; 2007; 152(12):2217-24. PubMed ID: 17891330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
